Logo image of ELOX

ELOXX PHARMACEUTICALS INC (ELOX) Stock Fundamental Analysis

NASDAQ:ELOX - Nasdaq - US29014R2022 - Common Stock - Currency: USD

3.82  -0.23 (-5.68%)

After market: 2.8 -1.02 (-26.7%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to ELOX. ELOX was compared to 193 industry peers in the Pharmaceuticals industry. ELOX has a bad profitability rating. Also its financial health evaluation is rather negative. ELOX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ELOX had negative earnings in the past year.
ELOX had a negative operating cash flow in the past year.
In the past 5 years ELOX always reported negative net income.
ELOX had a negative operating cash flow in each of the past 5 years.
ELOX Yearly Net Income VS EBIT VS OCF VS FCFELOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

ELOX's Return On Assets of -407.11% is on the low side compared to the rest of the industry. ELOX is outperformed by 95.69% of its industry peers.
Industry RankSector Rank
ROA -407.11%
ROE N/A
ROIC N/A
ROA(3y)-149.72%
ROA(5y)-125.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELOX Yearly ROA, ROE, ROICELOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 1K

1.3 Margins

ELOX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELOX Yearly Profit, Operating, Gross MarginsELOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -5K -10K -15K -20K

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for ELOX remains at a similar level compared to 1 year ago.
The debt/assets ratio for ELOX is higher compared to a year ago.
ELOX Yearly Shares OutstandingELOX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ELOX Yearly Total Debt VS Total AssetsELOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

ELOX has an Altman-Z score of -82.04. This is a bad value and indicates that ELOX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -82.04, ELOX is not doing good in the industry: 96.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -82.04
ROIC/WACCN/A
WACCN/A
ELOX Yearly LT Debt VS Equity VS FCFELOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

ELOX has a Current Ratio of 0.25. This is a bad value and indicates that ELOX is not financially healthy enough and could expect problems in meeting its short term obligations.
ELOX has a worse Current ratio (0.25) than 94.74% of its industry peers.
ELOX has a Quick Ratio of 0.25. This is a bad value and indicates that ELOX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ELOX (0.25) is worse than 94.26% of its industry peers.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.25
ELOX Yearly Current Assets VS Current LiabilitesELOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.20% over the past year.
EPS 1Y (TTM)43.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ELOX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.36% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.16%
EPS Next 2Y24.25%
EPS Next 3Y16.7%
EPS Next 5Y23.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELOX Yearly Revenue VS EstimatesELOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
ELOX Yearly EPS VS EstimatesELOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELOX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELOX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELOX Price Earnings VS Forward Price EarningsELOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELOX Per share dataELOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8 -10

4.3 Compensation for Growth

ELOX's earnings are expected to grow with 16.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.25%
EPS Next 3Y16.7%

More info and screens

0

5. Dividend

5.1 Amount

ELOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELOXX PHARMACEUTICALS INC

NASDAQ:ELOX (10/13/2023, 8:00:02 PM)

After market: 2.8 -1.02 (-26.7%)

3.82

-0.23 (-5.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11 2023-08-11/amc
Earnings (Next)11-08 2023-11-08/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners156.5%
Ins Owner Change5.48%
Market Cap10.70M
Analysts85.71
Price Target61.2 (1502.09%)
Short Float %0.08%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.75%
Min EPS beat(2)-24.78%
Max EPS beat(2)-10.73%
EPS beat(4)2
Avg EPS beat(4)-3.03%
Min EPS beat(4)-24.78%
Max EPS beat(4)19.79%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.09%
PT rev (3m)20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.23%
EPS NY rev (1m)-10.63%
EPS NY rev (3m)4.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.36
EYN/A
EPS(NY)-7.54
Fwd EYN/A
FCF(TTM)-7.69
FCFYN/A
OCF(TTM)-7.67
OCFYN/A
SpS0
BVpS-6.64
TBVpS-6.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -407.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-149.72%
ROA(5y)-125.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.25
Altman-Z -82.04
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.17%
EPS Next Y51.16%
EPS Next 2Y24.25%
EPS Next 3Y16.7%
EPS Next 5Y23.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y47.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.61%
OCF growth 3YN/A
OCF growth 5YN/A